Creative Medical Technology Reports Continued Operating Losses and No Revenue in Q2 2025

Creative Medical Technology Holdings, Inc. reported its financial results for the second quarter and first half of 2025, revealing a continued trend of operating losses and minimal revenue generation. For the three months ended June 30, 2025, the company did not generate any revenue, a decrease from $8,000 in the same period last year. For the six months ended June 30, 2025, revenue totaled $3,000, down from $8,000 in the prior year. The company’s operating loss for the second quarter was $1,263,520, compared to a loss of $1,625,306 in the same quarter of 2024. The net loss for the first half of 2025 was $2,871,400, an increase from a loss of $2,599,272 in the first half of 2024.

The company’s total assets increased to $7,105,228 as of June 30, 2025, up from $6,669,143 at the end of 2024. This growth was primarily driven by an increase in cash and cash equivalents, which rose to $6,544,120 from $5,940,402. However, total liabilities remained stable at $277,644, resulting in stockholders' equity increasing to $6,827,584 from $6,341,499. The increase in equity was attributed to the exercise of warrants and stock-based compensation, despite the ongoing net losses.

Operationally, Creative Medical Technology has focused on advancing its product offerings, particularly in the fields of immunotherapy and regenerative medicine. The company has made significant strides in its clinical trials, including the initiation of a Phase I/II trial for its AlloStemSpine® Chronic Lower Back Pain treatment. The trial aims to evaluate the safety and efficacy of its cell therapy, with patient recruitment having commenced in September 2023. Additionally, the company has received FDA clearance for its Type I Diabetes investigational new drug application, allowing it to begin clinical trials for this indication.

Despite these advancements, the company faces challenges in revenue generation and market penetration. The filing noted that the lack of revenue is a significant concern, as the company has limited marketing and distribution capabilities. The management acknowledged that the biotechnology sector is characterized by rapid technological changes and competition from well-established companies, which could hinder its ability to capture market share. Looking ahead, Creative Medical Technology remains focused on its clinical development programs and aims to enhance its product offerings to improve financial performance. The company continues to evaluate strategic partnerships and collaborations to bolster its market presence and operational capabilities.